Piramal Pharma Ltd Upgraded to Sell by MarketsMOJO Amid Mixed Financial and Technical Signals

Quality Assessment: Persistent Profitability Concerns

Piramal Pharma’s quality metrics continue to reflect significant weaknesses, particularly in profitability and debt management. The company reported negative financial results for the third consecutive quarter in Q3 FY25-26, with Profit Before Tax (excluding other income) plunging to a loss of ₹95.99 crores, a staggering decline of 2,577.2% compared to the previous four-quarter average. Similarly, Profit After Tax fell by 755.0% to ₹95.08 crores in losses, while Earnings Per Share (EPS) hit a low of ₹-1.03.

These figures underscore the company’s low ability to generate returns for shareholders, as reflected in its average Return on Equity (ROE) of just 0.32%. Furthermore, the high Debt to EBITDA ratio of 3.83 times signals a strained capacity to service debt, raising concerns about financial stability. Despite these challenges, the company has demonstrated some operational resilience, with operating profit growing at an annualised rate of 111.53% over the long term, suggesting pockets of underlying strength.

Valuation: Trading at a Discount Amid Fair Capital Efficiency

From a valuation standpoint, Piramal Pharma presents a mixed picture. The stock is currently priced at ₹165.70, modestly up 1.56% on the day, but significantly below its 52-week high of ₹241.00. Its Enterprise Value to Capital Employed ratio stands at 2.1, indicating a fair valuation relative to the capital invested in the business. Additionally, the company’s Return on Capital Employed (ROCE) of 2.7% suggests moderate capital efficiency, though this remains below industry averages.

Importantly, the stock trades at a discount compared to its peers’ historical valuations, which could appeal to value-oriented investors. However, this discount is tempered by the company’s underperformance in the last year, where it has generated a negative return of -17.52%, contrasting sharply with the BSE500’s positive 11.06% return over the same period.

Financial Trend: Mixed Signals Amid Declining Profitability

The financial trend for Piramal Pharma remains challenging. While the company has shown healthy long-term growth in operating profit, the recent quarterly results paint a bleak picture. Net sales have grown at a modest annual rate of 7.96% over the past five years, which is relatively low for a pharmaceutical company expected to capitalise on innovation and market expansion.

Profitability metrics have deteriorated sharply, with profits falling by 372.9% over the past year. The company’s inability to generate consistent positive earnings has contributed to its underperformance relative to the broader market. This is further evidenced by the stock’s negative returns over one year (-17.52%) compared to the Sensex’s 8.52% gain and the BSE500’s 11.06% rise.

Institutional investors hold a significant 45.35% stake in the company, indicating confidence from sophisticated market participants who typically conduct rigorous fundamental analysis. This level of institutional ownership may provide some stability amid volatility.

Technicals: Upgrade Driven by Improved Market Indicators

The primary catalyst for the recent upgrade in Piramal Pharma’s investment rating is the shift in technical indicators. The technical grade has improved from bearish to mildly bearish, signalling a tentative positive momentum in the stock’s price action. Key technical metrics reveal a nuanced picture:

• MACD (Moving Average Convergence Divergence) remains bearish on the weekly chart but has softened to mildly bearish on the monthly timeframe.
• Relative Strength Index (RSI) shows no clear signal on both weekly and monthly charts, indicating a neutral momentum.
• Bollinger Bands suggest mild bearishness on both weekly and monthly scales, reflecting moderate volatility with a slight downward bias.
• Daily moving averages continue to be bearish, signalling short-term caution.
• KST (Know Sure Thing) indicator is bearish weekly but lacks a monthly reading, suggesting mixed momentum signals.
• Dow Theory analysis shows a mildly bullish trend on the weekly chart, while the monthly chart shows no definitive trend.
• On-Balance Volume (OBV) is mildly bullish weekly, indicating some accumulation by investors, but no clear monthly trend.

These technical improvements, particularly the shift from outright bearishness to mild bearishness and the emergence of mildly bullish volume indicators, have contributed to the upgrade from Strong Sell to Sell. The stock’s recent price action supports this view, with a 1-week return of 4.44% outperforming the Sensex’s -1.14% over the same period.

Comparative Performance and Market Context

Over longer time horizons, Piramal Pharma has delivered mixed returns. While the stock has generated an impressive 97.58% return over three years, it has significantly underperformed in the last year with a -17.52% return. This contrasts with the Sensex’s 8.52% gain and the BSE500’s 11.06% rise over the same period, highlighting recent challenges in maintaining momentum.

The 52-week trading range between ₹148.30 and ₹241.00 reflects considerable volatility, with the current price of ₹165.70 closer to the lower end of this spectrum. This suggests the stock is trading at a discount, which may attract value investors willing to tolerate near-term risks for potential long-term gains.

Outlook and Investor Considerations

Despite the upgrade to a Sell rating, Piramal Pharma remains a stock with significant risks. The company’s weak profitability, high leverage, and recent negative earnings trends caution investors to remain vigilant. However, the improved technical outlook and fair valuation metrics provide some grounds for cautious optimism.

Investors should closely monitor upcoming quarterly results for signs of a turnaround in profitability and debt servicing capacity. Additionally, the high institutional ownership may provide some support, as these investors typically have access to deeper fundamental insights and may act as stabilising forces in volatile markets.

In summary, the rating upgrade reflects a technical improvement rather than a fundamental turnaround. The company’s financial health and growth prospects remain under pressure, warranting a conservative stance for most investors.

Summary of Ratings and Scores

Piramal Pharma’s current Mojo Score stands at 31.0, with a Mojo Grade of Sell, upgraded from Strong Sell on 13 Feb 2026. The Market Cap Grade is 3, indicating a mid-tier market capitalisation relative to peers. The technical trend shift from bearish to mildly bearish was the primary driver behind this rating change, while quality and financial trend parameters remain subdued.

Final Thoughts

For investors seeking exposure to the Pharmaceuticals & Biotechnology sector, Piramal Pharma offers a complex risk-reward profile. While the stock’s valuation and technical indicators have improved, fundamental challenges persist. A cautious approach is advisable, with attention to evolving financial results and market conditions.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →